CCA
HAE icon

Catalyst Capital Advisors’s Haemonetics HAE Stock Holding History

Catalyst Capital Advisors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-44,100
Closed -$5.07M – 267
2019
Q4 		$5.07M Sell
44,100
-900
-2% -$109K 0.16% 75
2019
Q3 		$5.68M Buy
45,000
+36,900
+456% +$4.68M 0.19% 75
2019
Q2 		$975K Buy
+8,100
New +$797K 0.03% 131

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Catalyst Capital Advisors's HAE Position: Q1 2020 in Review

Catalyst Capital Advisors sold out of Haemonetics (HAE) in Q1 2020, closing a stake of 44,100 shares — an estimated $5.07M sold.

Catalyst Capital Advisors first reported a position in HAE in Q2 2019 and held it in 3 quarters. The position peaked at $5.68M in Q3 2019. 269 funds tracked by Wall St. Rank hold HAE as of Q1 2020.

  • Catalyst Capital Advisors reported no remaining Haemonetics position as of Q1 2020 after selling out during the quarter.
  • Catalyst Capital Advisors sold 44,100 Haemonetics shares in Q1 2020, an estimated $5.07M.
  • Catalyst Capital Advisors first reported a position in Haemonetics in Q2 2019 and held it in 3 quarters.
  • Catalyst Capital Advisors's Haemonetics position peaked at $5.68M in Q3 2019.
  • 269 funds tracked by Wall St. Rank held Haemonetics as of Q1 2020.

Based on Catalyst Capital Advisors's 13F filing for Q1 2020, filed 12 May 2020.